Preclinical analysis of the novel Hsp90 inhibitor NVP-HSP990 in multiple myeloma cells

被引：0
|
作者：
Stuehmer, T. [1 ]
Iskandarov, K. [1 ]
Nick, H. [2 ]
Einsele, H. [1 ]
Chatterjee, M. [1 ]
Bargou, R. C. [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Internal Med 2, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[2] Novartis Inst BioMed Res, Basel, Switzerland
来源：
ONKOLOGIE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [1] Preclinical Activity of the Novel Orally Bioavailable HSP90 Inhibitor NVP-HSP990 against Multiple Myeloma Cells
    Stuehmer, Thorsten
    Iskandarov, Kamol
    Gao, Zhenhai
    Bumm, Thomas
    Grella, Evelyn
    Jensen, Michael R.
    Einsele, Hermann
    Chatterjee, Manik
    Bargou, Ralf C.
    ANTICANCER RESEARCH, 2012, 32 (02) : 453 - 462
  • [2] CELLULAR ACTIVITY OF A NOVEL HSP90 INHIBITOR NVP-HSP990 FOR TREATMENT OF HUMAN GLIOBLASTOMA
    Wu, Jing
    Shen, Ruijun
    Puduvalli, Vinay
    Koul, Dimpy
    Yung, W. K. Alfred
    NEURO-ONCOLOGY, 2010, 12 : 91 - 91
  • [3] NVP-HSP990, a potent and orally active Hsp90 inhibitor for cancer treatment
    Gao, Z.
    Machajewski, T.
    Menezes, D.
    Jensen, M. R.
    ANNALS OF ONCOLOGY, 2011, 22 : 31 - 31
  • [4] Identification and development of NVP-HSP990, a potent and orally active Hsp90 inhibitor for cancer treatment
    Gao, Zhenhai
    Machajewski, Timothy
    Menezes, Daniel
    Jensen, Michael Rugaard
    Yu, Karen
    Guy, Chantale
    CANCER RESEARCH, 2011, 71
  • [5] The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases
    Lamottke, Britta
    Kaiser, Martin
    Mieth, Maren
    Heider, Ulrike
    Gao, Zhenhai
    Nikolova, Zariana
    Jensen, Michael R.
    Sterz, Jan
    von Metzler, Ivana
    Sezer, Orhan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 88 (05) : 406 - 415
  • [6] The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo
    Menezes, Daniel L.
    Taverna, Pietro
    Jensen, Michael R.
    Abrams, Tinya
    Stuart, Darrin
    Yu, Guoying Karen
    Duhl, David
    Machajewski, Timothy
    Sellers, William R.
    Pryer, Nancy K.
    Gao, Zhenhai
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 730 - 739
  • [7] A NOVEL HSP90 INHIBITOR, NVP-HSP990, TARGETS CELL CYCLE REGULATORS TO PRODUCE AN ANTI-GLIOMA EFFECT IN OLIG2-EXPRESSING GLIOMA STEM CELLS
    Fu, Jun
    Koul, Dimpy
    Yao, Jun
    Wang, Shuzhen
    Yuan, Ying
    Sulman, Erik P.
    Colman, Howard
    Lang, Frederick F.
    Yung, W. K. A.
    NEURO-ONCOLOGY, 2012, 14 : 33 - 33
  • [8] Preclinical anti-myeloma activity of the novel Hsp90 ATPase inhibitor NVP-BEP800
    Stuehmer, Thorsten
    Jensen, Michael
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    Bargou, Ralf
    CANCER RESEARCH, 2009, 69
  • [9] RETRACTED: Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor-Initiating Cells (Retracted Article)
    Fu, Jun
    Koul, Dimpy
    Yao, Jun
    Wang, Shuzhen
    Yuan, Ying
    Colman, Howard
    Sulman, Erik. P.
    Lang, Frederick. F.
    Yung, W. K. Alfred
    CANCER RESEARCH, 2013, 73 (10) : 3062 - 3074
  • [10] Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990
    Milanovic, Dusan
    Firat, Elke
    Grosu, Anca Ligia
    Niedermann, Gabriele
    RADIATION ONCOLOGY, 2013, 8
12345